arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

REVELATION BIOSCIENCES, INC.

REVB

$1.12 ▼ -0.04 (-3.85%) at close

7 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

REVELATION BIOSCIENCES, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -80.9% ↗

FCF / Share $-13.32

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-8.91M

↑ +40.7% —

FCF / Share Free cash flow per share

$-13.32

↑ +66.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	97.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-12366.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	94.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-251.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	96.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	40.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-12405.6% Weak ↓ Weak Declining Year-over-year change in net income	98.9% Excellent ↑ Excellent Improving Year-over-year change in net income	9.7% Fair ↑ Fair Improving Year-over-year change in net income	-635.2% Weak Weak Year-over-year change in net income	-44718.6% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	—	—	—	—	73.4% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.93x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.22x Good ↓ Good Declining Free cash flow relative to reported net income Optimal: > 1x	60.59x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-80.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-133.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-102.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-815.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	9491.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-78.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-120.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-197.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-585.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-100.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-771%)	—	-1.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-112%)	—	—	28.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+91%)	100.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+567%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-10.70M	$-6.50M	$-11.99M	$-5.25M	$-1.27M	$-11.73K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-23.95	$-1.05K	$-8.44	$-149.20	$-42.50	$-1.13K	—
Free Cash Flow per Share (USD)	$-13.32	—	—	—	$-39.79	$-149.84	—
Book Value per Share (USD)	$5.59	—	—	—	$-0.35	$-5.21K	—
Tangible Book Value per Share (USD)	$5.59	—	—	—	$-0.35	$-5.21K	—
Basic Weighted Avg Shares (shares)	620,785	14,293	14,246	72,585	282,035	1,446	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$8.81M	$4.65M	$6.58M	$962.32K	$-229.61K	$-2.78M	$-3.64K
Total Equity (USD)	$8.86M	$4.71M	$6.65M	$1.05M	$-99.47K	$-5.69M	$-3.64K

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$27.06K	$27.92K	$25.05K	$25.05K	$16.78K	—	—
Net Income, GAAP (USD)	$-8.91M	$-15.04M	$-120.25K	$-10.83M	$-11.99M	$-1.63M	$-3.64K
Operating Cash Flow (USD)	$-8.27M	$-18.32M	$-7.29M	$-11.22M	$-11.09M	$-216.66K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

REVELATION BIOSCIENCES, INC.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare REVB with peers